1. South Korea Stocks

  2. •

    Utilities

  3. •

    Renewable Utilities
HLB Life Science Co., Ltd.

HLB Life Science Co., Ltd.

067630.KQ
HLB Life Science Co., Ltd.KR flagKOSDAQ
3,125.00
KRW
+15.00
- -
380.77BMarket Cap

Total Valuation

HLB Life Science Co., Ltd. carries a market capitalization of 380.77B, placing it among publicly traded companies globally. Its enterprise value stands at 608.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap380.77B
Enterprise Value608.89B

Share Statistics

HLB Life Science Co., Ltd. currently has 121.85M shares outstanding.

Shares Outstanding121.85M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 9.01, and the price-to-book ratio stands at -15.59.

PE RatioN/A
PS Ratio9.01
PB Ratio-15.59
P/TBV Ratio1.91
P/FCF Ratio-131.85
P/OCF Ratio-19.76

Enterprise Valuation

EV / Sales11.82
EV / EBITDAN/A
EV / EBITN/A
EV / FCF68.95

Financial Position

HLB Life Science Co., Ltd. maintains a current ratio of 0.55, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.81, indicating elevated leverage, while an interest coverage ratio of -1.78 demonstrates limited ability to service its debt obligations.

Current Ratio0.55
Quick Ratio0.15
Debt / Equity55.81
Debt / EBITDA-7.52
Interest Coverage-1.78

Financial Efficiency

Return on Equity (ROE)-488.50
Return on Assets (ROA)-10.17
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover8.19

Taxes

Income Tax356.70M
Effective Tax RateN/A

Stock Price Statistics

HLB Life Science Co., Ltd.'s stock has declined approximately -36.61258% over the past 52 weeks. The 50-day moving average sits at 3,524.70, while the 200-day moving average is 3,860.73.

Beta (5Y)N/A
52-Week Price Change-36.61258%
50-Day Moving Average3,524.70
200-Day Moving Average3,860.73
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, HLB Life Science Co., Ltd. generated 51.51B in revenue and converted that into -50.45B in net income, yielding earnings per share of -414.86. EBITDA reached -21.81B, while operating income came in at -21.81B.

Revenue51.51B
Gross Profit-1.45B
Operating Income-21.81B
Pretax Income-50.25B
Net Income-50.45B
EBITDA-21.81B
EBIT-21.81B
Earnings Per Share (EPS)-414.86

Balance Sheet

HLB Life Science Co., Ltd. holds 19.75B in cash and equivalents against 164.07B in total debt, resulting in a net debt position of 146.93B. Total book value stands at -29.78B, with working capital of -58.41B providing operational flexibility.

Cash & Cash Equivalents19.75B
Total Debt164.07B
Net Debt146.93B
Equity (Book Value)-29.78B
Book Value Per Share-244.11
Working Capital-58.41B

Cash Flow

HLB Life Science Co., Ltd. produced -23.49B in operating cash flow over the past twelve months. After subtracting -19.97B in capital expenditures, free cash flow totaled -43.47B - equivalent to -356.29 per share.

Operating Cash Flow-23.49B
Capital Expenditures-19.97B
Free Cash Flow-43.47B
FCF Per Share-356.29

Margins

HLB Life Science Co., Ltd. operates with a gross margin of -2.81, reflecting its pricing power and cost economics. The operating margin of -42.33 and net profit margin of -97.94 provide insight into operational efficiency.

Gross Margin-2.81
Operating Margin-42.33
Pretax Margin-97.56
Profit Margin-97.94
EBITDA Margin-42.33

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-4.59
FCF Yield-0.76

Stock Splits

HLB Life Science Co., Ltd.'s most recent stock split took place on December 28, 2022 with a 500000:525849 split ratio.

Last Split Date12/28/2022
Split Ratio500000:525849

Scores

HLB Life Science Co., Ltd. posts an Altman Z-Score of 0.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.95